Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to... SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.
- Mechanism
- Curator reviewed
Through investigation of the mechanisms underlying SGN-30's antitumor activity, SGN-30 treatment was found to activate NF-kappaB and modulation of several messages including the growth regulator p21WAF1/CIP1 (p21) and cellular adhesion marker ICAM-1. p21 protein level changes are believed to be associated with arresting cell growth.
- Primary indication
- Investigated for use/treatment in autoimmune diseases, cancer/tumors (unspecified), lymphoma (non-hodgkin's), and lymphoma (unspecified).Curator reviewed
- Code names
- CAC-10 · SGN-30
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Brentuximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account